For research use only. We do not sell to patients.
Research lipid catalog

Ionizable Lipid Products

Explore 848 lipid and RNA delivery products. Search the full catalog or browse by research category.

Search covers product name, catalog number, synonyms, available CAS numbers and categories. Spaces, hyphens and common punctuation are ignored. Duplicate legacy records are consolidated under one canonical product result.

6177 products · Showing 5961–5980 · 20 per page
DC Chemicals lipid expertise

Built for ionizable-lipid discovery and RNA delivery research

DC Chemicals supports formulation and delivery research with a broad, searchable portfolio of cationic and ionizable lipids. The current directory brings together 848 unique research-use products, with product specifications, pricing, chemical structures and literature-linked formulation data added as each record is verified.

Our experience spans complex lipid synthesis, purification, analytical release and process development. For custom molecules or larger-scale requirements, our team can discuss route development, technical specifications and scale-up options for the intended research workflow.

Learn about cationic and ionizable lipids →
848unique products in the current searchable directory
Evidence-awareliterature modules appear only after source review
Research supportformulation context, handling guidance and calculators
Proprietary innovation · Co-development · GMP

From proprietary lipid design to GMP-grade custom synthesis

DC Chemicals has independently developed ionizable-lipid structures supported by company-owned intellectual property, and selected proprietary lipid programs have advanced to GMP-stage development.

We welcome joint development with customers—from molecular design and lipid synthesis through route and process development. We can also support custom synthesis of GMP-grade ionizable lipids to agreed technical specifications and quality requirements.

Discuss a co-development project →
Proprietary ionizable-lipid structuresCollaborative molecular designCustom lipid synthesisProcess development and scale-upGMP-grade project support

Cat. No.Product NameField of ApplicationChemical Structure

Olmesartan medoxomil(Olmetec; Benicar; CS 866) is an angiotensin II receptor antagonist which is used as an anti-hypertensive.

Olmesartan MedoxoMil
OlmesartanFeatured

For the detailed information of Olmesartan, the solubility of Olmesartan in water, the solubility of Olmesartan in DMSO, the solubility of Olmesartan in PBS buffer, the animal experiment(test) (test) of Olmesartan, the cell expriment (test) of Olmesartan, the in vivo, in vitro and clinical trial test of Olmesartan, the EC50, IC50,and Affinity of Olmesartan,, please contact DC Chemicals.

Olmesartan
NVP-QAV-572Featured

NVP-QAV-572 is a potent PI3K kianse inhibitor with IC50 of 10 nM. IC50 value: 10 nM Target: PI3K Preparation of 5-phenylthiazol-2-ylureas as phosphatidylinositol 3-kinase (PI3 kinase) inhibitors. By Budd, Emma; Fox Hayler, Judy; Ian, Bruce; Legrand, Darren Mark; Cox, Brian From PCT Int. Appl. (2007), WO 2007134827 A1 20071129. For the detailed information of NVP-QAV-572, the solubility of NVP-QAV-572 in water, the solubility of NVP-QAV-572 in DMSO, the solubility of NVP-QAV-572 in PBS buffer, the animal experiment (test) of NVP-QAV-572, the cell expriment (test) of NVP-QAV-572, the in vivo, in vitro and clinical trial test of NVP-QAV-572, the EC50, IC50,and Affinity of NVP-QAV-572, Please contact DC Chemicals.

NVP-QAV-572

Potent, ATP-competitive and selective dual PI3K and PDK1 inhibitor in vitro and in vivo, with IC50 values to be 56, 444, 34, 117 and 240 nM For PI3K p110 alpha, beta, delta and gamma and PDK1 kinases, respectively.For the detailed information of NVP-BAG956(BAG 956), the solubility of NVP-BAG956(BAG 956) in water, the solubility of NVP-BAG956(BAG 956) in DMSO, the solubility of NVP-BAG956(BAG 956) in PBS buffer, the animal experiment (test) of NVP-BAG956(BAG 956), the cell expriment (test) of NVP-BAG956(BAG 956), the in vivo, in vitro and clinical trial test of NVP-BAG956(BAG 956), the EC50, IC50,and Affinity of NVP-BAG956(BAG 956), Please contact DC Chemicals.

NVP-BAG956(BAG 956)
NVP-231Featured

NVP-231 is a potent, reversible inhibitor of ceramide kinase (IC50 = 12 nM). It has minimal effect on several other lipid kinases, including sphingosine kinases 1 and 2.3 In cells in which exogenous short chain ceramide is converted to C1P, resulting in cell death, NVP-231 prevents both C1P synthesis and cell death.In mouse dermal microvascular endothelial cells, where ceramide kinase increases capillary-like tube formation, NVP-231 (100 nM) inhibits C1P formation as well as tube formation. For the detailed information of NVP-231, the solubility of NVP-231 in water, the solubility of NVP-231 in DMSO, the solubility of NVP-231 in PBS buffer, the animal experiment (test) of NVP-231, the cell expriment (test) of NVP-231, the in vivo, in vitro and clinical trial test of NVP-231, the EC50, IC50,and affinity,of NVP-231, For the detailed information of NVP-231, the solubility of NVP-231 in water, the solubility of NVP-231 in DMSO, the solubility of NVP-231 in PBS buffer, the animal experiment (test) of NVP-231, the cell expriment (test) of NVP-231, the in vivo, in vitro and clinical trial test of NVP-231, the EC50, IC50,and affinity,of NVP-231, Please contact DC Chemicals.

NVP-231
NMI 8739Featured

In Vitro NMI 8739 is a dopamine D2 autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine. NMI 8739 reduces nitric oxide (NO) production in LPS-stimulated RAW264.7 Macrophages. NMI 8739 elicits concentration-dependent suppression of CCL-20, MCP-1 and IL-6 Release in RAW264.7 macrophages after LPS-stimulation. Production of PGE2 is concentration-dependently suppressed with a reduction of 25.3% at 100 nM NMI 8739 and a 75% reduction for 1 μM NMI 8739. 2 μM NMI 8739 significantly inhibits IL-6 and CCL-20 release up to 49% and 37%, respectively.

NMI 8739
NigakinoneFeatured

Nigakinone is one of the most abundant alkaloids responsible for the major pharmacological activities of Kumu.

Nigakinone
NetupitantFeatured

Netupitant is a highly potent and selective, orally active neurokinin-1 receptor antagonist with Ki of 0.95 nM. IC50 value: 0.95 nM (Ki) in vitro: Netupitant also dose-dependently inhibited the SP response as expected from an NK1 receptor antagonist. Importantly, when both palonosetron and netupitant were present, they exhibited an enhanced inhibition of the SP response compared to either of the two antagonists alone. in vivo: In mice the intrathecal injection of SP elicited the typical scratching, biting and licking response that was dose-dependently inhibited by Netupitant given intraperitoneally in the 1-10mg/kg dose range. In gerbils, foot tapping behavior evoked by the intracerebroventricular injection of a NK(1) agonist was dose-dependently counteracted by Netupitant given intraperitoneally (ID(50) 1.5mg/kg) or orally (ID(50) 0.5mg/kg). For the detailed information of Netupitant, the solubility of Netupitant in water, the solubility of Netupitant in DMSO, the solubility of Netupitant in PBS buffer, the animal experiment (test) of Netupitant, the cell expriment (test) of Netupitant, the in vivo, in vitro and clinical trial test of Netupitant, the EC50, IC50,and affinity,of Netupitant, For the detailed information of Netupitant, the solubility of Netupitant in water, the solubility of Netupitant in DMSO, the solubility of Netupitant in PBS buffer, the animal experiment (test) of Netupitant, the cell expriment (test) of Netupitant, the in vivo, in vitro and clinical trial test of Netupitant, the EC50, IC50,and affinity,of Netupitant, Please contact DC Chemicals.

Netupitant
NepafenacFeatured

For the detailed information of Nepafenac, the solubility of Nepafenac in water, the solubility of Nepafenac in DMSO, the solubility of Nepafenac in PBS buffer, the animal experiment(test) (test) of Nepafenac, the cell expriment (test) of Nepafenac, the in vivo, in vitro and clinical trial test of Nepafenac, the EC50, IC50,and Affinity of Nepafenac,, please contact DC Chemicals.

Nepafenac
PP3Featured

Negative control for the Src kinase inhibitor PP2. Inhibits EGFR kinase (IC50 = 2.7 μM). For the detailed information of PP3, the solubility of PP3 in water, the solubility of PP3 in DMSO, the solubility of PP3 in PBS buffer, the animal experiment (test) of PP3, the cell expriment (test) of PP3, the in vivo, in vitro and clinical trial test of PP3, the EC50, IC50,and affinity,of PP3, For the detailed information of PP3, the solubility of PP3 in water, the solubility of PP3 in DMSO, the solubility of PP3 in PBS buffer, the animal experiment (test) of PP3, the cell expriment (test) of PP3, the in vivo, in vitro and clinical trial test of PP3, the EC50, IC50,and affinity,of PP3, Please contact DC Chemicals.

PP3
NefiracetamFeatured

For the detailed information of Nefiracetam, the solubility of Nefiracetam in water, the solubility of Nefiracetam in DMSO, the solubility of Nefiracetam in PBS buffer, the animal experiment(test) (test) of Nefiracetam, the cell expriment (test) of Nefiracetam, the in vivo, in vitro and clinical trial test of Nefiracetam, the EC50, IC50,and Affinity of Nefiracetam,, please contact DC Chemicals.

Nefiracetam
NedocromilFeatured

Nedocromil is an inhaled anti-inflammatory agent For the preventive management of asthma. IC50 Value: Target: Cysteinyl Leukotriene Receptor(CYSLTR) in vitro: in vivo: Nedocromil sodium (10(-4) M) decreased LTB4 releasability and intracellular 5-HETE concentrations in zymosan-stimulated AM from asthmatic patients, and was shown to decrease the LTC4 or LTE4-promoted Formation of LTB4 and 5-HETE . Eight atopic asthmatic subjects inhaled nedocromil or placebo be Fore the AMP challenge. Spirometry and FE(NO) were measured at intervals over a 24-h period. Nedocromil gave partial protection against this decrease in FE(NO). The time-FE(NO) curve (AUC(0-24)) differed significantly between nedocromil and placebo: 2.7% (-3.6 to -9) vs. -6.6% (-12 to -1.3) FE(NO) changes h(-1), P < 0.002, respectively. Nedocromil protected against AMP-induced bronchoconstriction (AMP PC(20)) [nedocromil 182 (72.5-291) mg mL(-1) vs. placebo 21.7 (10.7-33) mg mL(-1), P < 0.002] . Nedocromil sodium relieved symptoms of allergic conjunctivitis and further support a role For nedocromil sodium in the prevention of allergic conjunctivitis . Nedocromil, 2 to 20 mg/kg, significantly (P<0.05) inhibited cell adhesion and emigration, as well as myeloperoxidase release, in wild-type but not Anx-A1(-/-) mice .For the detailed information of Nedocromil, the solubility of Nedocromil in water, the solubility of Nedocromil in DMSO, the solubility of Nedocromil in PBS buffer, the animal experiment (test) of Nedocromil, the cell expriment (test) of Nedocromil, the in vivo, in vitro and clinical trial test of Nedocromil, the EC50, IC50,and Affinity of Nedocromil, Please contact DC Chemicals.

Nedocromil
NCT-501Featured

NCT-501 is a potent and selective inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1) with IC50 of 40 nM.

NCT-501
NBD-557Featured

NBD-557 is a potentially HIV-1 inhibitor. NBD-557, is small molecule organic compounds with drug-like properties. It showed potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels. A systematic study showed that NBD-557 target viral entry by inhibiting the binding of HIV-1 envelope glycoprotein gp120 to the cellular receptor CD4 but did not inhibit reverse transcriptase, integrase, or protease, indicating that they do not target the later stages of the HIV-1 life cycle to inhibit HIV-1 infection. NBD-557 potent inhibitors of both X4 and R5 viruses tested in CXCR4 and CCR5 expressing cell lines, respectively, indicating that its anti-HIV-1 activity is not dependent on the coreceptor tropism of the virus. A surface plasmon resonance study, which measures binding affinity, clearly demonstrated that NBD-557 bind to unliganded HIV-1 gp120 but not to the cellular receptor CD4. NBD-557 was active against HIV-1 laboratory-adapted strains including an AZT-resistant strain and HIV-1 primary isolates, indicating that NBD-557 can potentially be further modified to become potent HIV-1 entry inhibitors.

NBD-557

For the detailed information of Naratriptan hydrochloride, the solubility of Naratriptan hydrochloride in water, the solubility of Naratriptan hydrochloride in DMSO, the solubility of Naratriptan hydrochloride in PBS buffer, the animal experiment(test) (test) of Naratriptan hydrochloride, the cell expriment (test) of Naratriptan hydrochloride, the in vivo, in vitro and clinical trial test of Naratriptan hydrochloride, the EC50, IC50,and Affinity of Naratriptan hydrochloride,, please contact DC Chemicals.

Naratriptan hydrochloride

NAN-190 is a 5-HT1A receptor antagonist with Ki of 0.6 nM; also potently blocks the α2-adrenergic receptor; antagonizes the stimulation by norepinephrine of phosphoinositide turnover in rat cortical slices.AnxietyPreclinical

NAN-190 hydrobromide

For the detailed information of Nalidixic acid (NegGram), the solubility of Nalidixic acid (NegGram) in water, the solubility of Nalidixic acid (NegGram) in DMSO, the solubility of Nalidixic acid (NegGram) in PBS buffer, the animal experiment(test) (test) of Nalidixic acid (NegGram), the cell expriment (test) of Nalidixic acid (NegGram), the in vivo, in vitro and clinical trial test of Nalidixic acid (NegGram), the EC50, IC50,and Affinity of Nalidixic acid (NegGram),, please contact DC Chemicals.

Nalidixic acid (NegGram)
NabumetoneFeatured

Nabumetone(BRL14777) is a non-steroidal anti-inflammatory drug and its active metabolite inhibits the COX.Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid family. Nabumetone itself is non-acidic and, following absorption, it undergoes extensive first-pass metabolism to form the main circulating active metabolite (6-MNA) which is a much more potent inhibitor of preferentially COX-2. Nabumetone displays acute anti-inflammatory activity in the carrageenan-induced oedema model in rats and the ultraviolet-induced erythema model in guinea-pigs. Its activity in these tests is greater than that of aspirin but less than that of naproxen and indomethacin. In the cotton pellet-induced granuloma model in the rat, Nabumetone is active and produces no signs of toxicity at doses much greater than the lowest effective dose, unlike aspirin, naproxen or indomethacin. Nabumetone is also active in the adjuvant-induced arthritis test in rats. In contrast to aspirin, indomethacin and naproxen, Nabumetone is well tolerated by the stomach of fasted rats at doses in excess of those with anti-inflammatory activity.

Nabumetone

Page 299 of 309 · Browse all 6177 products

Jump to a product page

Featured literature product: HX1 · DCL0028

HX1 is a hydroxyzine-derived ionizable lipid with acetal-containing tails, studied in lipid nanoparticles for brain mRNA delivery and CRISPR–Cas9 delivery. It was the lead in the reported in vivo brain-delivery screen; evidence is preclinical and formulation-dependent.

Read full formulation and performance →